PRS16 - MODELED SURVIVAL GAINS OF PATIENTS WITH CYSTIC FIBROSIS (CF) AGED ≥12 YEARS HETEROZYGOUS FOR F508DEL-CFTR AND A RESIDUAL FUNCTION MUTATION (F508DEL/RF) TREATED WITH THE CF TRANSMEMBRANE CONDUCTANCE REGULATOR MODULATOR (CFTRM) TEZACA ...
Abstract
Authors
A. Lopez Y. Yang B. Loop C. Chandler T. Liou M. Konstan C. Pelligra A. Ward J. Rubin